Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 84.5M | - |
| Gross profit | 38.2M | - |
| Net profit | 4.7M | - |
| EBITDA | 18.37M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €265.3M |
Number of shares | 10.07M |
52-week high/low | €26.50 - €19.20 |
| Dividends | No |
Beta | 0.70 |
P/E ratio | 37.64 |
PEG ratio | 0.18 |
P/B ratio | 1.44 |
P/S ratio | 1.54 |
Company profile
Eurobio Scientific Société anonyme designs, develops, and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; EBX-044 PCR test to enable the identification of SARS-CoV-2 variants; and licensed products comprise AlloMap, a gene-expression profiling based blood test for the surveillance of heart-transplant patients. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
| Name | Eurobio Scientific |
| CEO | Denis Fortier |
| Headquarters | Les Ulis,
if France |
| Website | |
| Industry | Insurance |
| IPO | 02/28/2020 |
| Employees | 443 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALERS.PA |
Frankfurt | E8TN.F |
Düsseldorf | E8TN.DU |
Paris | ALERS.PA |
München | E8TN.MU |
